Effective pharmacologic treatment exists for most patients suffering from allergic rhinitis (AR). However, both in clinical trials and in real-life studies, many patients are dissatisfied with treatment. Physicians often use multiple therapies, in an attempt to improve symptom control, often with limited evidence of success. Novel treatment options are needed and must consider unmet medical needs.status: publishe
Allergic rhinitis is a worldwide disease, which occurred from 17% to 40% of the population in differ...
Introduction: Allergic rhinitis (AR) is a very common disease, caused by environmental aeroallergen,...
The efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone ...
Effective pharmacologic treatment exists for most patients suffering from allergic rhinitis (AR). Ho...
Allergic rhinitis (AR) has a major negative impact on patients' quality of life (QoL) and carries a ...
Allergic rhinitis (AR) is increasing in prevalence and becoming more difficult to treat. There is a ...
There is no shortage of pharmacologic treatments available for the management of allergic rhinitis (...
Rhinitis is often the first symptom of allergy but is frequently ignored and classified as a nuisanc...
Introduction: Recent developments in drug research in the indication allergic rhinitis (AR) include ...
Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the cu...
MP29-02 (Dymista), a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone ...
Because of its burden on patient's lives and its impact on asthma, allergic rhinitis must be treated...
Background: Moderate-to-severe allergic rhinitis (AR) is a challenge to treat, with many patients us...
Abstract Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many ...
Globally allergic rhinitis (AR) has created many health issues and its treatment becomes a challenge...
Allergic rhinitis is a worldwide disease, which occurred from 17% to 40% of the population in differ...
Introduction: Allergic rhinitis (AR) is a very common disease, caused by environmental aeroallergen,...
The efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone ...
Effective pharmacologic treatment exists for most patients suffering from allergic rhinitis (AR). Ho...
Allergic rhinitis (AR) has a major negative impact on patients' quality of life (QoL) and carries a ...
Allergic rhinitis (AR) is increasing in prevalence and becoming more difficult to treat. There is a ...
There is no shortage of pharmacologic treatments available for the management of allergic rhinitis (...
Rhinitis is often the first symptom of allergy but is frequently ignored and classified as a nuisanc...
Introduction: Recent developments in drug research in the indication allergic rhinitis (AR) include ...
Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the cu...
MP29-02 (Dymista), a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone ...
Because of its burden on patient's lives and its impact on asthma, allergic rhinitis must be treated...
Background: Moderate-to-severe allergic rhinitis (AR) is a challenge to treat, with many patients us...
Abstract Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many ...
Globally allergic rhinitis (AR) has created many health issues and its treatment becomes a challenge...
Allergic rhinitis is a worldwide disease, which occurred from 17% to 40% of the population in differ...
Introduction: Allergic rhinitis (AR) is a very common disease, caused by environmental aeroallergen,...
The efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone ...